Comprehensive medication guide to Emgality including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$150 copay with commercial insurance; prior authorization and step therapy typically required.
Estimated Cash Pricing
$700–$950 per month without insurance; Eli Lilly savings card may reduce cost to as low as $0 for the first month and $35/month after.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Emgality (Galcanezumab-gnlm) is a prescription biologic medication manufactured by Eli Lilly and Company. It belongs to the CGRP (calcitonin gene-related peptide) antagonist class and is a humanized monoclonal antibody. Emgality is FDA-approved for two indications:
Emgality is self-administered as a subcutaneous injection once monthly in the abdomen, thigh, or back of the upper arm.
![Why Is Emgality So Hard to Find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2Fa00a4b554473c9c26a7e7374b43d2fb9ea07d070-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
![How to Find a Doctor Who Can Prescribe Emgality Near You [2026 Guide]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F6d8c21f9583dbdc450c064c9fa0ebdc0b2e8af99-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Emgality works by binding to and neutralizing calcitonin gene-related peptide (CGRP), a neuropeptide that plays a key role in migraine and cluster headache pathophysiology. CGRP promotes blood vessel dilation and pain signaling in the brain. By blocking CGRP before it can bind to its receptors, Emgality helps prevent migraine attacks and reduces cluster headache frequency.
Unlike oral CGRP antagonists (gepants), Emgality is a monoclonal antibody that stays active in the body for weeks, which is why it only needs to be injected once a month. It is not metabolized by the liver or kidneys — instead, it is broken down naturally through catabolism like other antibodies.
120 mg/mL prefilled pen (autoinjector)
used for migraine prevention
120 mg/mL prefilled syringe
used for migraine prevention
100 mg/mL prefilled pen
used for episodic cluster headache (3 pens = 300 mg dose)
Emgality (Galcanezumab) has a findability score of 45 out of 100, meaning it is frequently difficult to find in stock. Emgality has been listed on the ASHP drug shortage list due to increased demand, and patients have reported intermittent difficulty filling prescriptions at major chain pharmacies like CVS and Walgreens since late 2022. As a biologic with no biosimilar available, supply constraints from manufacturer Eli Lilly can lead to localized shortages. Using a tool like Medfinder can help you locate pharmacies that currently have Emgality in stock near you.
Emgality can be prescribed by several types of healthcare providers, including:
Telehealth consultations are also available for Emgality prescriptions. Most insurance plans require prior authorization before covering Emgality, and many require step therapy (trying and failing other preventive medications first). You can use Medfinder to find providers who prescribe Emgality near you.
No, Emgality is not a controlled substance. It has no DEA scheduling and carries no risk of abuse or dependence. Emgality is a monoclonal antibody biologic that does not affect the central nervous system in a way that could lead to addiction. It does not require special prescribing procedures associated with controlled substances.
Serious but rare side effects include hypersensitivity reactions (difficulty breathing, hives, rash), anaphylaxis, and angioedema. Emgality carries no boxed warning. Contact your healthcare provider immediately if you experience signs of a severe allergic reaction after injection.
Know what you need? Skip the search.
Aimovig (Erenumab)
CGRP receptor antagonist monoclonal antibody, monthly subcutaneous injection (70 mg or 140 mg). Targets the CGRP receptor rather than the ligand itself.
Ajovy (Fremanezumab)
Anti-CGRP monoclonal antibody, dosed monthly (225 mg) or quarterly (675 mg) via subcutaneous injection.
Vyepti (Eptinezumab)
Anti-CGRP monoclonal antibody administered as an IV infusion every 3 months in a healthcare setting.
Qulipta (Atogepant)
Oral CGRP receptor antagonist (gepant), taken daily as a tablet. Available in 10 mg, 30 mg, and 60 mg doses.
Prefer Emgality? We can find it.
No major drug-drug interactions
majorhave been identified
No clinically significant moderate interactions
moderatehave been identified
minor interactions
minorOnly with other CGRP antibodies (Erenumab, Fremanezumab, Eptinezumab) — combining them would be redundant, not dangerous
No known food or drink interactions
moderateEmgality is an effective and well-tolerated CGRP monoclonal antibody for preventing migraines and treating episodic cluster headaches. However, with a findability score of just 45 out of 100, patients may face challenges locating it in stock due to ongoing supply constraints. The high cash price of $700–$950 per month makes savings programs essential — Eli Lilly's savings card can reduce costs to as little as $0–$35 per month for commercially insured patients, and the Lilly Cares patient assistance program provides the medication free to qualifying uninsured patients.
If you're struggling to find Emgality at your local pharmacy, try using Medfinder to check real-time availability at pharmacies near you. You can also ask your prescriber about specialty pharmacies, which may have more reliable stock.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini